Login / Signup

Predictors of functional response and remission with desvenlafaxine 50 mg and 100 mg: a pooled analysis of randomized, placebo-controlled studies in patients with major depressive disorder.

Claudio N SoaresDalia B WajsbrotMatthieu Boucher
Published in: CNS spectrums (2019)
Early improvement in SDS total score was predictive of functional outcomes for patients treated with desvenlafaxine 50 mg, desvenlafaxine 100 mg, or placebo.
Keyphrases
  • major depressive disorder
  • placebo controlled
  • double blind
  • phase iii
  • bipolar disorder
  • clinical trial
  • phase ii
  • open label
  • study protocol
  • phase ii study
  • locally advanced